Fundz

Aurinia Pharma

Bilbao, Autonomous Community of the Basque Country, Spain · Biopharma, Biotechnology, Health Care

Aurinia Pharma is a biopharmaceutical company focused on developing and commercializing therapeutics to treat kidney diseases. The company is dedicated to advancing innovative solutions to improve patients' lives. Aurinia's flagship product is designed to address serious medical needs in its therapeutic area. With a small team and specialized expertise, they are positioned for growth in the biopha

Key facts

Headquarters
Bilbao, Autonomous Community of the Basque Country, Spain
Employees
130
Industries
Biopharma, Biotechnology, Health Care
Status
Public (AUPH)
Website
auriniapharma.com
LinkedIn
Company page

Recent activity at Aurinia Pharma

  • : SEC 8-K (8.01): On August 19, 2026, Aurinia Pharmaceuticals Inc. announced via a press release that it has entered into a settlement agreement with Teva Pharmaceuticals Inc. to resolve patent infringement litigation related to Teva’s attempt to market a generic version of voclosporin oral capsules. This agreement aims to prevent further litigation and secures Aurinia's market position for the branded drug. The press release containing the details of the agreement is incorporated as Exhibit 99.1. The strategic implications of this settlement are significant as it allows Aurinia to continue its commercial efforts without the overhang of litigation, thereby stabilizing its market presence and potentially affecting revenue streams positively.
  • : SEC 8-K (5.07): On June 3, 2026, Aurinia Pharmaceuticals Inc. held its annual general meeting of shareholders where shareholders elected five nominees to the Board of Directors: Kevin Tang, Jeffrey Bailey, Kathy Goetz, Craig Johnson, and Tina S. Nova. The results showed that Kevin Tang received the highest support with 96.59% of votes in favor, while Craig Johnson and Tina S. Nova had the lowest support with 86.50% and 86.89% respectively. The meeting signifies a key change in the governance structure, with these board members serving until the next annual meeting in 2027. This change aims to enhance the leadership and strategic direction of the corporation, especially as it continues to advance its pharmaceutical initiatives.
  • : SEC 8-K (2.01): On May 8, 2026, Aurinia Pharmaceuticals Inc. completed a significant acquisition involving Kezar Life Sciences, Inc. as outlined in a Merger Agreement dated March 30, 2026. Aurinia Pharma U.S., Inc., acting as the Buyer, conducted a tender offer for all outstanding shares of Kezar's common stock at a price of $6.955 per share in cash, alongside a contingent value right (CVR). By the expiration of the offer on May 8, 2026, 5,927,580 shares were tendered, which accounted for approximately 80.24% of all outstanding shares, fulfilling the minimum tender condition required for the acquisition. This strategic move is poised to enhance Aurinia's portfolio and market position in the pharmaceutical industry, pending further developments outlined in the CVR agreement dated May 11, 2026.
  • : SEC 8-K (2.01): On May 8, 2026, Aurinia Pharmaceuticals Inc. completed a tender offer to acquire all outstanding shares of common stock of Kezar Life Sciences, Inc. This acquisition was facilitated through an Agreement and Plan of Merger dated March 30, 2026, involving Aurinia Pharma U.S., Inc., and its subsidiary Aurinia Merger Sub, Inc. The transaction is significant as it marks Aurinia's strategic expansion into new markets and enhances its product pipeline. This acquisition underscores Aurinia's commitment to growth and innovation in the biopharmaceutical sector.
  • : SEC 8-K (1.01): On March 30, 2026, Aurinia Pharma U.S., Inc. entered into a Merger Agreement with Kezar Life Sciences, Inc., proposing an acquisition of Kezar's outstanding shares for $6.955 in cash plus one contingent value right (CVR). The agreement includes a tender offer for the shares, with Parent required to commence the offer by April 13, 2026. The merger is expected to close in the second quarter of 2026, pending certain conditions. Under the agreement, all options to purchase shares of Kezar common stock will be converted into cash based on the offer price if they are in-the-money, impacting both common stockholders and option holders significantly.
  • : Aurinia acquires Kezar Life Sciences for $6.955/share
  • : Kevin Tang Appointed CEO of Aurinia Pharmaceuticals
  • : Aurinia Pharmaceuticals Appoints Kevin Tang as Chief Executive Officer and Ryan Cole as Chief Operating Officer
  • : SEC 8-K (5.02): On March 23, 2026, Aurinia Pharmaceuticals Inc. appointed Kevin Tang as Chief Executive Officer, alongside Ryan Cole as Chief Operating Officer, and Michael Hearne as Chief Financial Officer. Kevin Tang, 59, previously served as Chair of the Board since 2024 and opted not to receive any remuneration for his new role. Ryan Cole, 39, will receive an annual base salary of $300,000 and a target bonus of 50%, in addition to 150,000 common shares as a new hire option. These appointments are strategically significant as they bring experienced leadership to Aurinia amidst its growth aspirations in the life sciences sector.
  • : SEC 8-K (5.02): On March 20, 2026, Aurinia Pharmaceuticals Inc. announced the appointment of Kevin Tang as the new Chief Executive Officer and principal executive officer, effective March 23, 2026. Mr. Tang, aged 59, has extensive experience in the life sciences sector, previously serving as Chair of the Board since 2024 and currently leading Tang Capital Management, LLC. His leadership in other companies, including La Jolla Pharmaceutical and Odonate Therapeutics, indicates a significant strategic direction for Aurinia. This change in management is crucial for stakeholders as it may impact future business strategies and operational focus.

Leadership

  • Keely Dahl, Director, Medical Affairs
  • Archie Stone, Vice President, Head of Medical Affairs
  • Kevin Tang, Principal
  • Ryan Cole, Chief Operating Officer
  • Kevin Tang, Chief Executive Officer

Verified email and direct lines for Aurinia Pharma’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Aurinia Pharma in the news

Companies similar to Aurinia Pharma

About Aurinia Pharma: questions and answers

What does Aurinia Pharma do?

Aurinia Pharma is a biopharmaceutical company focused on developing and commercializing therapeutics to treat kidney diseases. The company is dedicated to advancing innovative solutions to improve patients' lives. Aurinia's flagship product is designed to address serious medical needs in its therapeutic area. With a small team and specialized expertise, they are positioned for growth in the biopha

Where is Aurinia Pharma headquartered?

Aurinia Pharma is headquartered in Bilbao, Autonomous Community of the Basque Country, Spain.

How many employees does Aurinia Pharma have?

Aurinia Pharma has about 130 employees.

Who leads Aurinia Pharma?

Archie Stone is a Vice President, Head of Medical Affairs at Aurinia Pharma.

What is the latest news on Aurinia Pharma?

On Aug 19, 2026, SEC 8-K (8.01): On August 19, 2026, Aurinia Pharmaceuticals Inc. announced via a press release that it has entered into a settlement agreement with Teva Pharmaceuticals Inc. to resolve patent infringement litigation related to Teva’s attempt to market a generic version of voclosporin oral capsules.

Is Aurinia Pharma a public company?

Yes. Aurinia Pharma is publicly traded under the ticker AUPH.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Aurinia Pharma across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.